The tale of the Danish pharmaceutical industry begins in the Danish soil. Until just a few decades ago, Denmark was first and foremost an agricultural country; the processing of agricultural goods (milk to cheese, grain to beer) led to ground-breaking research in proteins, amino acids and enzymes.
Novo Nordisk, Scandinavia’s largest company in terms of market value, towers above other Danish companies in the sector with its strong position in insulin preparations for diabetes. Novo Nordisk commands a 27% share of the global diabetes market – a market growing at about twice the speed of the pharmaceutical industry in general.
Lundbeck, another larger pharmaceutical company from Denmark, has leading products for the treatment of psychiatric and neurological disorders, including anxiety, depression, Alzheimer’s disease and other types of dementia and LEO Pharma specialises in treatments for psoriasis, eczema and other skin disorders.
Founded on solid research, innovation and a well established Healthcare sector, Denmark now boasts the world’s second largest pharmaceutical industry, as measured on a per capita basis and with the more life style diseases, the medicines needed could very well be coming from Denmark as the pharmaceutical industry is prepared to combat tomorrows diseases with ”The Medicines Of Tomorrow”.
Danish footprints in the fight against life style
diseases can be found around the world. In 2014 the Novo Nordisk owned Steno Diabetes Centre opened its first overseas office in Kuala Lumpur to train health care professionals in
The risk of lifestyle diseases and mental imbalance associated with low physical activity and increased stress around the world are a close match with the established specialties of large Danish Pharmaceutical companies.